1. |
Hayakawa 2017 Japan |
181 |
R |
N |
73 (36-93) |
140/41 |
NA |
N |
<T2-78>T2-103 |
79 |
NA |
NA |
P-101 U-70 Both-10 |
LG-52 HG-129 |
NA |
30 |
53 (1-253) |
-LVI-PD-1 expression in tumor nest |
CSS PFS |
6 |
2. |
Hong 200519 Hong B, Park S, Hong JH, Kim CS, Ro JY, Ahn H. Prognostic value of lymphovascular invasion in transitional cell carcinoma of upper urinary tract. Urology. 2005;65:692-6. Epub 2005/04/19. Korea |
73 |
R |
N |
59.1 |
NA |
NA |
Y-37 |
Ta-15 T1-18 T2-9 T3-27 T4-4 |
18 |
NA |
NA |
P-40 U-33 |
G1-6 G2-35 G3-32 |
13 |
NA |
42.3 |
-LVI - grade -stage |
DSS RFS |
6 |
3. |
Hsieh 201520 Hsieh MC, Sung MT, Chiang PH, Huang CH, Tang Y, Su YL. The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma. PLoS One. 2015;10:e0129268. Epub 2015/06/27. Taiwan |
206 |
R |
N |
63 (22-84) |
138/68 |
NA |
NA |
NA |
NA |
NA |
NA |
Upper urinarytract-119 Bladder-84 Both-3 |
|
206 |
53 |
134.5 |
-Histopathological Variant -Renal function -Visceral metastasis |
OS PFS OS |
6 |
4. |
Hurel 201322 Hurel S, Roupret M, Ouzzane A, Rozet F, Xylinas E, Zerbib M, et al. Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2013;111:1199-207. Epub 2013/05/09. France |
551 |
R |
Y |
69.4 (61.8-76.4) |
365/186 |
O-551 |
Y |
Ta/Tis-142 T1-124 T2-53 T3-193 T4-39 |
163 |
NA |
NA |
P-302 U-169 Both-80 |
G1-80 G2-251 G3-415 |
79 |
NA |
26.8 (10.348.7) |
-Multifocal -pT3 stage -LVI -positive surgical margin(MFS) |
CSS RFS MFS |
6 |
5. |
Ichimura 201423 Ichimura T, Morikawa T, Kawai T, Nakagawa T, Matsushita H, Kakimi K, et al. Prognostic significance of CD204-positive macrophages in upper urinary tract cancer. Ann Surg Oncol. 2014;21:2105-12. Epub 2014/02/05. Japan |
171 |
R |
N |
70 |
119/52 |
NA |
Y |
Ta/Tis-44 T1-31 T2-18 T3-69 T4-9 |
74 |
NA |
NA |
P-103 U-68 |
LG-19 HG-152 |
NA |
NA |
56 |
-High CD204* -LVI -LN Mets |
RFS MFS CSS |
6 |
6. |
Ike da 2017 Japan |
441 |
R |
Y |
69 (62-75) |
319/122 |
O-247 L-194 |
Y |
Ta/Tis-86 T1-92 T2-81 T3-158 T4-24 |
156 |
NA |
NA |
P-245 U-196 |
G1/2-305 G3-130 |
100 |
37 |
35.7 |
-T stage - Lymph node status -Grade3 -LVI -positive STSM |
DFS CSS |
7 |
7. |
Kang 201526 Kang HW, Jung HD, Ha YS, Kim TH, Kwon TG, Byun SS, et al. Preoperative Underweight Patients with Upper Tract Urothelial Carcinoma Survive Less after Radical Nephroureterectomy. J Korean Med Sci. 2015;30:1483-9. Epub 2015/10/02. Korea |
440 |
R |
Y |
NA |
305/135 |
NA |
Y |
Ta/Tis-31 T1-135 T2-101 T3-155 T4-8 |
76 |
NA |
NA |
P-159 U-219 Both-62 |
LG-110 HG-330 |
78 |
NA |
31 (15-57) |
-Locally advanced stage -Node positive status -LVI -Margin status |
OS DSS |
8 |
8. |
Kim DS 201029 Kim DS, Lee YH, Cho KS, Cho NH, Chung BH, Hong SJ. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology. 2010;75:328- 32. Epub 2009/12/19. Korea |
238 |
R |
N |
64.1 (25-91) |
164/74 |
NA |
Y |
Ta-T2-131 T3-107 |
31 |
NA |
NA |
P-134 U-104 |
LG-95 HG-143 |
NA |
24 |
53.4 (3-240) |
-Tumor architecture -squamous differentiation -LVI -Tumor grade |
RFS CSS |
7 |
9. |
Kim JK 201731 Kim JK, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol. 2017;35:458 e9-e15. Epub 2017/03/30. Korea |
452 |
R |
N |
64±10.2 |
347/105 |
O-332 L-120 |
Y |
T0/a/is/1-187 T2-75 T3/4-188 |
99 |
NA |
NA |
P-223 U-165 Both-64 |
LG-59 HG-81 |
110 |
41 |
67.8 (0-254) |
-Age -T stage - multifocality -Positive STSM -tumor location -variant histology -LVI |
OS CSS |
7 |
10. |
Kim SH 2015 Korea |
371 |
R |
N |
64.7 (57.7) |
287/84 |
O-271 L-100 |
Y |
pT0/a/is/1-162 pT2-63 pT3/4-146 |
71 |
NA |
NA |
P-183 Ur40 Both-48 |
LG-125 HG-246 |
85 |
28 |
50.8 |
-LRUN - stage -grade |
OS CSS |
7 |
11. |
Lee Sang 2006 Korea |
119 |
R |
N |
62 (36-90) |
92/27 |
NA |
Y |
Ta/T1-38 pT2-4-81 |
30 |
19 |
>10% macroscopic necrosis |
P-54 U-65 |
G1/2-76 G3-43 |
40 |
NA |
41 (2-164) |
-T stage -LVI -Tumor necrosis |
DSS |
7 |
12. |
Lee Young 201436 Lee YJ, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS One. 2014;9:e107027. Epub 2014/09/06. Korea |
341 |
R |
N |
63.1 (56.4-70.5) |
301/40 |
NA |
Y |
Ta/Tis-54 T1-81 T2-58 T3-144 T4-4 |
70 |
NA |
NA |
NA |
G1-39 G2-206 G3-96 |
86 |
27 |
66.8 (30-95.3) |
-Age -T stage -LVI -positive STSM -Nodal metastasis -Histological variant |
CSS OS |
7 |
13. |
Lee Hsiang 201436 Lee YJ, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Impact of squamous and glandular differentiation on oncologic outcomes in upper and lower tract urothelial carcinoma. PLoS One. 2014;9:e107027. Epub 2014/09/06. Taiwan |
250 |
R |
N |
68 |
108/142 |
O-166 L-84 |
Y |
Ta/Tis-40 T1-53 T2-73 T3-70 T4-14 |
60 |
NA |
NA |
P-128 U-122 |
LG-55 HG-195 |
42 |
NA |
41 |
-T stage - Lymph node involvement -LVI -Concomitant bladder tumor(RFS) |
CSS MFS RFS |
7 |
14. |
LI Tao 201937 Li T, Xu H, Yang L, Tan P, Wei Q. Predictive value of preoperative lymphocyte-to-monocyte ratio for patients with upper tract urothelial carcinoma. Clin Chim Acta. 2019;492:50-6. Epub 2019/02/15. China |
704 |
R |
N |
66±11.4 |
401/303 |
O-474 L-230 |
Y |
</=T2-359 >/=T3-345 |
107 |
NA |
NA |
P-375 U-202 Both-127 |
LG-185 HG-519 |
286 |
162 |
39 (34-43) |
-Low lymphocyte to monocyte ratio -Tumor size >/=3cm -High tumor grade -Advance tumor stage(>/=T3) -Lymph node invasion -Tumor architecture -Concomitant variant histology -Albumin to globulin ratio |
CSS RFS OS |
7 |
15. |
LI Yifan 201938 Li Y, Fang D, Bao Z, He A, Guan B, He S, et al. High aspartate transaminase/alanine transaminase ratio predicts poor prognosis in patients with localized upper tract urothelial cancer: a propensity score-matched study in a large Chinese center. Onco Targets Ther. 2019;12:2635-48. Epub 2019/05/23. China |
602 |
R |
N |
66.77±9.90 |
285/317 |
NA |
Y |
Ta-6 T1-322 T2-2956T3-238 T4-24 |
46 |
114 |
NA |
P-310 U-292 |
G1-15 G2-342 G3-245 |
NA |
105 |
6138-102) |
-High AST/ALT -T stage -N stage -Age -Gender -Tumor location -Tumor size -Glandular differentiation |
CSS OS RFS |
7 |
16. |
Liu 201339 Liu JY, Li YH, Zhang ZL, Ye YL, Liu ZW, Yao K, et al. Age-specific effect of gender on upper tract urothelial carcinoma outcomes. Med Oncol. 2013;30:640. Epub 2013/06/20. China |
421 |
R |
Y |
62 (51-70) |
285/136 |
O-364 L-57 |
Y |
Ta/Tis/T1-157 T2-91 T3-144 T4-29 |
101 |
NA |
NA |
P-225 U-196 |
G1-87 G2-128 G3-206 |
88 |
NA |
NA |
-Female gender -LVI -Tumor grade -Tumor stage - N stage |
CSS |
6 |
17. |
Masson 2013 France |
519 |
R |
Y |
68.4 (61.2-76.5) |
342/177 |
O-519 |
Y |
Ta/is/1246 pT2/3/4-273 |
361 |
NA |
NA |
P-289 U-154 Both-76 |
G1-46 G2-167 G3-306 |
80 |
39 |
27 (10.2-48.7) |
-T stage -LVI -margin status -Adjuvant chemotherapy |
CSS MFS |
6 |
18. |
Matsumoto 201142 Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int. 2011;108:E304-9. Epub 2011/04/22. Japan |
2163 |
R |
Y |
69 (61-76) |
1478/685 |
O-1790 L-373 |
Y |
T0-10 Ta-450 Tis-36 T1-488 T2-401 T3-667 T4-111 |
481 |
496 |
NA |
NA |
LG-655 HG-1508 |
224 |
NA |
36 (15.3-71.1) |
-Age -T stage -Tumor grade -LVI -Tumor architecture -N stage |
RFS CSS |
7 |
19. |
Nakagawa 201744 Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, et al. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. World J Urol. 2017;35:1569-75. Epub 2017/04/12. Japan |
109 |
R |
Y |
71 (64-77) |
67/42 |
NA |
Y |
T3-104 T4-5 |
78 |
NA |
NA |
P-50 U-23 Both-36 |
G1-0 G2-40 G3-69 |
43 |
NA |
46.5 (23.2-76.7) |
-Adjuvant chemotherapy lower nuclear grade -absence of hydronephrosis |
RFS CSS |
8 |
20. |
Ouzzane 2012 France |
714 |
R |
Y |
70 (60-75) |
484/228 |
NA |
Y |
Ta/Tis-131 T1-216 T2-124 T3-205 T4-40 |
157 |
NA |
NA |
P-388 U-236 Both-90 |
G1-71 G2-244 G3-399 |
NA |
NA |
27 (10-50) |
-Age -T stage - surgical margin |
CSS MFS OS |
6 |
21. |
Qin 201746 Qin C, Liang EL, Du ZY, Qiu XY, Tang G, Chen FR, et al. Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases: A retrospective cohort study. Medicine (Baltimore). 2017;96:e6945. Epub 2017/05/26. China |
346 |
R |
N |
66.61± 9.897 |
206/140 |
NA |
N |
Ta/is/1258 pT2/3/4-88 |
NA |
18 |
NA |
P-175 U-171 |
LG-59 HG-287 |
169 |
50 |
21 (10-36) |
-T stage -Tumor grade -variant histology -adjuvant chemotherapy |
RFS CSS OS |
6 |
22. |
Kikuchi 200928 Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009;27:612-8. Epub 2008/12/17. japan |
1453 |
R |
Y |
69.7 (27-97) |
986/467 |
NA |
Y |
Ta-295 Tis-28 T1-317 T2-269 T3-475 T4-69 |
349 |
387 |
NA |
P-958 U-495 |
LG-516 HG-937 |
169 |
NA |
NA |
-T stage -Tumor grade -N stage -LVI |
CSS RFS |
6 |
23. |
Kawashima 2011 Japan |
93 |
R |
Y |
NA |
68/25 |
NA |
Y |
>T3-93 |
54 |
NA |
NA |
P-55 U-38 |
G1-6 G2-31 G3-56 |
38 |
11 |
NA |
-Adjuvant chemotherapy -Tumor grade -LVI -Sex -Histology |
CSS RFS |
6 |
24. |
Kim TH 201932 Kim TH, Hong B, Seo HK, Kang SH, Ku JH, Jeong BC. The Comparison of Oncologic Outcomes between Open and Laparoscopic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Korean Multicenter Collaborative Study. Cancer Res Treat. 2019;51:240-51. Epub 2018/04/25. South Korea |
1521 |
R |
Y |
65 (57-72) |
1127/394 |
O-906 L-615 |
Y |
Ta/Tis-235 T1-404 T2-255 T3-592 T4-35 |
332 |
NA |
NA |
P-682 U-565 Both-274 |
LG-485 HG-993 Missing-43 |
340 |
NA |
54.9 (32.7-89.7) |
-Previous bladder Tumor -Concomitant bladder tumor -Age -T stage -Tumor grade -LVI -Concomitant CIS -N stage |
IVRFS PFS CSS OS |
6 |
25. |
Kohada 201833 Kohada Y, Hayashi T, Goto K, Kobatake K, Abdi H, Honda Y, et al. Preoperative risk classification using neutrophil- lymphocyte ratio and hydronephrosis for upper tract urothelial carcinoma. Jpn J Clin Oncol. 2018;48:841-50. Epub 2018/08/08. Japan |
148 |
R |
N |
71 (64-78) |
112/36 |
NA |
Y |
Ta/1/2-82 T3/4-66 |
55 |
NA |
NA |
P-82 U-66 |
G1/2-60 G3-88 |
25 |
NA |
35.5 (12-66) |
-Elevated pre-op Neutrophll- lymphocytes ratio -Hydronephrosis -LVI |
CSS RFS |
7 |
26. |
Morizane 2015 Japan |
345 |
R |
Y |
74 (38-95) |
234/111 |
O-244 L-101 |
Y |
<T3-188>/=T3-152 |
102 |
NA |
NA |
P-140 U-205 |
Non G3- 222 G3-109 |
80 (23.2%) |
29 |
39.9 (6.1-160) |
-ECOG performance status -Number of tumor foci -Serum HB -eGFR -T stage -Histological variant -Tumor grade -Positive LN -INF -LVI -Positive margin |
CSS |
6 |
27. |
Makise 201540 Makise N, Morikawa T, Kawai T, Nakagawa T, Kume H, Homma Y, et al. Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma. Int J Clin Exp Pathol. 2015;8:7203-9. Epub 2015/08/12. Japan |
140 |
R |
N |
NA |
101/39 |
NA |
Y |
Ta/Tis-36 T1-25 T2-11 T3-60 T4-8 |
61 |
NA |
NA |
P-89 U-51 |
G1/2-63 G3-77 |
42 |
23 |
NA |
-T stage -N stage -LVI -Tumor grade -Age |
MFS CSS OS |
7 |
28. |
Zhang 201663 Zhang B, Song Y, Jin J, Zhou LQ, He ZS, Shen C, et al. Preoperative Plasma Fibrinogen Level Represents an Independent Prognostic Factor in a Chinese Cohort of Patients with Upper Tract Urothelial Carcinoma. PLoS One. 2016;11:e0150193. Epub 2016/03/02. China |
184 |
R |
N |
70 (60-74) |
84/100 |
O-125 L-59 |
Y |
Ta/1-73 T2/3/4-111 |
28 |
30 |
NA |
P-99 U-85 |
G1/2-117 G3-67 |
NA |
NA |
78 (34-92) |
-preoperative plasma fibrinogen level -Gender -T stage -Age>70 -Preoperative CKD4/5 |
OS CSS |
7 |
29. |
Su 201652 Su X, Fang D, Li X, Xiong G, Zhang L, Hao H, et al. The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. Biomed Res Int. 2016;2016:4368943. Epub 2017/01/11. China |
687 |
R |
N |
<3cm-69 (20-90)>3cm-68 (29-86) |
306/381 |
O-220 L-467 |
Y |
Ta/is/1-129 T2-242 T3-197 T4-19 |
NA |
79 |
NA |
P-380 U-307 |
G1-21 G2-368 G3-298 |
NA |
81 |
65 (3-144) |
-Older age -Male -presence of hydronephrosis -Advance T stage -Positive LN -preoperative ureteroscopy -Lower tumor grade -N0 status -Tumor multifocality |
CSS RFS |
7 |
30. |
Huang 2016 China |
481 |
R |
N |
65.8±11.1 |
311/170 |
O-318 L-163 |
Y |
Ta/1-248 T2/3/4-233 |
76 |
NA |
NA |
P-232 U-160 Multifocal-89 |
LG-163 HG-318 |
96 |
NA |
40 (24-64) |
-F-PLR score -Age >65 -Tumor multifocality -T stage -Higher grade -LVI Higher pN stage |
OS CSS |
6 |
31. |
Abe 20181 Abe T, Kondo T, Harabayashi T, Takada N, Matsumoto R, Osawa T, et al. Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection. Jpn J Clin Oncol. 2018;48:1001-11. Epub 2018/10/03. Japan |
214 |
R |
Y |
70.5 (35-93) |
151/63 |
0-100 L-114 |
Y 214 |
42/48/41/75/8 |
96 |
NA |
NA |
P-127 U-82 Both-5 |
100/113/ |
14/200 |
NA |
15 |
-T stage -LVI -Tumor number |
RFS CSF OS |
7 |
32. |
Akao 20082 Akao J, Matsuyama H, Yamamoto Y, Hara T, Kawai Y, Sakano S, et al. Clinical significance of lymphovascular invasion in upper urinary tract urothelial cancer. BJU Int. 2008;102:572-5. Epub 2008/05/20. Japan |
90 |
R |
N |
NA |
57/33 |
NA |
NA |
0/3/24/14/43/6 |
34 |
NA |
NA |
P-51 U-39 |
4/56/29 |
24/61 |
NA |
42 (2-179) |
-LVI -pT -pN - Tumor grade -Adjuvant therpy |
DSS |
6 |
33. |
Aydin 20193 Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, et al. Prognostic significance of BAP1 expression in high- grade upper tract urothelial carcinoma: a multi-institutional study. World J Urol. 2019;37:2419-27. Epub 2019/02/14. USA |
348 |
R |
Y |
70 (64-77) |
163/185 |
NA |
Yes (n=86) |
31/103/57/129/28 |
98 |
62 |
NA |
P-267 U-81 |
NA |
NA |
NA |
36 |
-T stage - LVI -Necrosis- Architecture |
RFS CSS OS |
7 |
34. |
Aziz 20144 Aziz A, Rink M, Gakis G, Kluth LA, Dechet C, Miller F, et al. Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Urol Int. 2014;93:352-60. Epub 2014/08/21. Germany |
265 |
R |
Y |
67.7 ± 9.85; 69.8 ± 8.85 |
169/96 |
NA |
Yes (n=59) |
106 (Ta-T1)/49/102/8 |
52 |
NA |
NA |
P- 57 U- 33 Both- 26 |
43/60/162 |
46/219 |
NA |
37 (9-48) |
-ECOG -Tumor multifocality -LN involvement -LVI |
RFS DSS ACS |
6 |
35. |
Bolenz 2008 Germany |
116 |
R |
N |
NA |
80/36 |
0-107 L-09 |
Y 27 |
9/3/23/28/42/11/20 |
36 |
17 |
10% |
P-84 U-32 |
12/58/46 |
NA |
NA |
38 |
-LVI -Pathological stage |
DSS |
7 |
36. |
Cha 20126 Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012;61:818-25. Epub 2012/01/31. USA |
2244 |
R |
Y |
69 (61.6-76.0) |
1502/742 |
NA |
Y-129 N-540 X-1575 |
516/46/537/444/606/80 |
484 |
NA |
NA |
P- 1449 U- 795 |
HG- 1838 LG- 406 |
NA |
NA |
45 |
-T stage -LN status -LVI -Architecture -CIS |
RFS CSM CSS |
7 |
37. |
Cho 20177 Cho YH, Hwang JE, Chung HS, Kim MS, Hwang EC, Jung SI, et al. The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. Int Urol Nephrol. 2017;49:1383-90. Epub 2017/05/10. Korea |
1049 |
R |
Y |
68.5 (60.5-74.3) |
759/290 |
NA |
505 |
106/316/201/403/23 |
202 |
NA |
NA |
P-489 U-306 Both-92 |
HG-745 LG-304 |
Y-300 |
NA |
40 (18.4-64.8) |
-T stage -N1 disease -Hydronephrosis -De Ret is Ratio |
RFS CSS OS |
8 |
38. |
Chromecki 2011 USA |
1169 |
R |
Y |
69 (3092) |
785/384 |
O-1014 L-155 |
Y 398 |
285/20/274/231/318/53 |
259 |
287 |
NA |
P-742 U-427 |
LG-179 HG-982 |
Y-78 |
NA |
37 (1-197) |
-Age -Stage -Grade -Architecture -Necrosis -LVI |
CSD OS |
7 |
39. |
Chung 20199 Chung HS, Hwang EC, Kim MS, Yu SH, Jung SI, Kang TW, et al. Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Score-Matched Analysis. Clin Genitourin Cancer. 2019;17:e394-e407. Epub 2019/02/21. Korea |
1173 |
R |
Y |
68.8 (61-74.6) |
849/324 |
NA |
540 |
Tis/Ta/T1-460 T2-230 T3/T4-483 |
236 |
NA |
NA |
P-542 U-537 Both-94 |
LG-343 HG-830 |
Y-357 |
93 (7.9%) |
NA |
-Preoperative anemia -HDN -LVI -VH |
RFS CSS OS |
7 |
40. |
Dalpiaz 201410 Dalpiaz O, Pichler M, Mannweiler S, Martin Hernandez JM, Stojakovic T, Pummer K, et al. Validation of the pretreatment derived neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. Br J Cancer. 2014;110:2531-6. Epub 2014/04/03. Austria |
171 |
R |
N |
69 +/− 10.1 |
107/64 |
NA |
NA |
T1-79 T2-4=92 |
NA |
21 |
NA |
P-95 U-76 |
G1-2=92 G3-4=79 |
NA |
NA |
31 (13-69) |
-p stage -Grade pHistological - Tumor necrosis |
CSS OS |
7 |
41. |
Ekmekci 201911 Ekmekci S, Kucuk U, Dere Y, Cakir E, Sayar HC, Ergani B, et al. 8-armed octopus: Evaluation of clinicopathologic prognostic factors of urothelial carcinoma of the upper urinary system. Turk J Med Sci. 2019;49:153-61. Epub 2019/02/16. Turkey |
74 |
R |
Y |
63.3 (40-84) |
60/14 |
NA |
64 |
pTa-1613/04/28/13 |
25 |
29 |
NA |
P-38 U-7 Both-29 |
NA |
NA |
22 (39.2%) |
43.5 +/− 48.7 |
-Tumor necrosis -Tumor differentiation -LN metastasis |
DFS OS |
7 |
42. |
Elawddy 201612 Elawdy MM, Taha DE, Elbaset MA, Abouelkheir RT, Osman Y. Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up. Clin Genitourin Cancer. 2016;14:e609-e15. Epub 2016/06/06. Osman |
305 |
R |
N |
59 +/− 11 |
262/43 |
O-268 L-24 Renalsparing-13 |
NA |
T0-3 Ta,is.1-196 T2-44 T3-61 T4-1 |
NA |
NA |
NA |
P-183 U-182 |
G0-3 G1-16 G2-195 G3-100 |
NA |
NA |
34 (6-300) |
-Tumor stage -Micropapillary variant |
CSS OS |
7 |
43. |
Fairey 2012 Canada |
849 |
R |
Y |
70.5 |
|
O-403 L-446 |
245 |
<=T1-186 T2-66 T3-89 T4-22 |
NA |
NA |
NA |
NA |
HG-274 LG-123 |
Y-94 |
NA |
2.2 (0.6-5.0) |
-T stage -Surgical approach -LN stage -Grade -Surgical margin |
OS DSS RFS |
6 |
44. |
Fang 201814 Fang D, He S, Xiong G, Singla N, Cao Z, Zhang L, et al. Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma. BMC Urol. 2018;18:22. Epub 2018/03/29. China |
612 |
R |
N |
Pelvis-65.29 +/− 11.11 Ureter-68.07 +/− 10.20 |
340/272 |
NA |
41 |
pTa-1=206 pT2-4=406 |
NA |
75 |
NA |
P-341 U-271 |
G1-19 G2-334 G3-259 |
NA |
NA |
64 |
-Necrosis -LN status -Architecture -Grade -CIS |
OS CSS |
7 |
45. |
Gao 201715 Gao X, Chen W, Zhang R, Wu C, Li Y, Zhu H, et al. Preoperative AST/ALT ratio predicts long-term survival after radical nephroureterectomy in patients with upper tract urothelial carcinoma. Internaional Journal of Clinical and Experimental Medicine. 2017;10:8. China |
259 |
R |
N |
67.53 |
187/179 |
O-80 L-179 |
24 |
<=pT2-171>=pT3-88 |
212 |
NA |
NA |
NA |
G1-59 G2-3=200 |
NA |
23 (8.8%) |
33.3 (15.5-64.2) |
-AST/ALT -Stage -Grade -Histology -Sarcomatoid differentiation |
OS PFS CSS Bladder recurrence free survival |
7 |
46. |
Godfrey 201216 Godfrey MS, Badalato GM, Hruby GW, Razmjoo M, McKieman JM. Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion. BJU Int. 2012;110:798-803. Epub 2012/02/09. USA |
211 |
R |
N |
70 (11.4) |
124/87 |
O-121 L-90 |
59 |
Ta-Tis=78 T1-41 T2-18 T3-71 T4-3 |
68 |
NA |
NA |
P-170 U-41 |
HG-134 LG-77 |
NA |
NA |
27 (11-65.5) |
-Race -LVI -High nuclear grade |
OS OSS |
6 |
47. |
Hara 201517 Hara T, Fujimoto H, Sakura M, Inokuchi J, Nishiyama H, Miyazaki J, et al. Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association. Int J Urol. 2015;22:1013-20. Epub 2015/08/06. Japan |
1172 |
R |
Y |
NA |
806/366 |
O-750 L-421 Missing data-1 |
1138 |
Ta-125 Tis-29 T1-344 T2-302 T3-240 T4-21 Tx-111 |
423 |
NA |
NA |
P-593 U-546 Both-32 Missing data-1 |
G0-1 G1-71 G2-528 G3-558 Missing data-14 |
179 |
NA |
55.8 |
-Age -Stage -LN -Metastasis -LVI -Infiltrative growth pattern |
OS RFS |
7 |
48. |
Inamoto 2011 Japan |
103 |
R |
N |
68.6 ±10.05 |
71/32 |
NA |
Y |
Tis/Ta/T1-43 T2-13 T3/T4-47 |
32 |
Nil |
NA |
- |
G1-20 G2-28 G3-55 |
- |
11 |
29 (14-63) |
-C reactive protein -BMI -Focality -Lymph.Node |
OS CSS RFS |
6 |
49. |
Saito 200747 Saito K, Kawakami S, Fujii Y, Sakura M, Masuda H, Kihara K. Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically. J Urol. 2007;178:2291-6; discussion 6. Epub 2007/10/16. Japan |
189 |
R |
N |
NA |
94/41 |
NA |
Y |
≤T2-73 T3-62 |
57 |
Nil |
NA |
59/76 |
LG-81 HG-54 |
30 |
- |
55 (3-232) |
-Age-pT-LVI |
CSS RFS |
6 |
50. |
Sakano 2014 Japan |
502 |
R |
Y |
72 (32-93) |
344/158 |
NA |
Y |
<3-290 ≥3-212 |
166 |
Nil |
NA |
221/232 |
LG-257 HG-233 |
144 |
60 |
41.4 (3-200) |
-pT -Grade -LVI -Variant Histology |
CSS |
7 |
51. |
Shibing 201550 Shibing Y, Turun S, Qiang W, Junhao L, Haichao Y, Shengqiang Q, et al. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol. 2015;33:204 e9-16. Epub 2015/03/25. China |
417 |
R |
N |
67 (26-86) |
246/171 |
NA |
Y |
Tis/Ta/T1-118 T2-79 T3-168 T4-52 |
74 |
Nil |
NA |
271/110 |
LG-100 HG-317 |
78 |
90 |
26 (12-54) |
-pT -Grade -L.Nodes -Tumor Size -SurgicalMargins |
OS CSS RFS |
7 |
52. |
Song 201951 Song SH, Ye CH, Lee S, Hong SK, Byun SS, Lee SE, et al. Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy. J Cancer Res Clin Oncol. 2019;145:2863-70. Epub 2019/09/11. Korea |
453 |
R |
N |
69 (52-80) |
320/133 |
O-164 L-143 Robotic-146 |
Y |
Ta-6 T1-127 T2-147 T3-145 T4-23 |
132 |
Nil |
NA |
161/201 |
G1-2 G2-225 G3-222 |
- |
- |
23.2 (0-172) |
-BMI -pT -LVI -L.Node -HDN -HTN |
OS CSS RFS |
7 |
53. |
Sung 201453 Sung HH, Cho J, Kwon GY, Jeon HG, Jeong BC, Seo SI, et al. Clinical significance of micropapillary urothelial carcinoma of the upper urinary tract. J Clin Pathol. 2014;67:49-54. Epub 2013/08/14. Korea |
386 |
R |
N |
64 (56-71) |
293/93 |
NA |
Y |
Ta/Tis-78 T1-85 T2-56 T3/T4-167 |
- |
Nil |
NA |
175/166 |
G1-20 G2-193 G3-161 |
- |
7 |
39 (21.1-70.6) |
-Age -Gender -Location -Grade -pT |
RFS CSS |
7 |
54. |
Tai 2015 Taiwan |
503 |
R |
N |
68 (60-74.8) |
249/254 |
NA |
Y |
Ta/Tis/T1-144 T2-31 T3-101 T4-4 |
49 |
Nil |
NA |
280/184 |
LG-135 HG-142 |
- |
- |
52 (23-77) |
-Grade -pT -LVI -Location |
OS RFS CSS |
6 |
55. |
Tan 2018 China |
668 |
R |
Y |
65.8 (54.4-77.2) |
380/288 |
NA |
Y |
≤ pT2-338 ≥ pT3-330 |
99 |
Nil |
NA |
353/196 |
LG-173 HG-495 |
281 |
- |
45 (21-74) |
-Focality -pT -L.Nodes -LVI -LDH |
CSS OS RFS MFS |
7 |
56. |
Tanaka 2012 Japan |
218 |
R |
Y |
69 (38-92) |
160/5 8 |
O-155 L-63 |
Y |
Ta-T1-75 T2-27 T3-107 T4-9 |
84 |
Nil |
NA |
130/88 |
LG-59 HG-159 |
42 |
- |
38 (3-187) |
-Plasma Fibrinogen -pT -LVI |
CSS RFS |
7 |
57. |
Tanaka 201556 Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, et al. Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis. Eur Urol Focus. 2015;1:54-63. Epub 2015/08/01. Japan |
394 |
R |
Y |
70 (63-77) |
289/105 |
NA |
Y |
Ta/T1-125 T2-57 T3-201 T4-11 |
170 |
Nil |
NA |
232/162 |
LG-128 HG-266 |
88 |
- |
30 (15-63) |
-pT -LVI -Plasma Fibrinogen |
CSS RFS ACM |
7 |
58. |
Tang 2015 China |
687 |
R |
N |
68 (20-90) |
306/381 |
NA |
Y |
T1-216 T2-217 T3-160 T4-13 |
- |
Nil |
NA |
339/267 |
G1-20 G2-354 G3-232 |
- |
81 |
65 (3-144) |
-Gender -pT -Variant Histology -Pre op -HDN |
RFS CSS |
7 |
59. |
Vartolomei 2015 Multicentre |
2274 |
R |
Y |
69 (61-76) |
1527/747 |
NA |
Y |
Ta-497 Tis-48 T1-532 T2-441 T3-671 T4-85 |
499 |
516 |
- |
1448/826 |
LG-367 HG-1907 |
- |
- |
40 (20-76) |
-pT -Grade -LVI -NLR -L.Node -Gender |
RFS CSS |
7 |
60. |
Waseda 2015 Japan |
1068 |
R |
Y |
70 (62-76) |
758/310 |
NA |
Y |
Ta-127 Tis-34 T1-186 T2-164 T3-518 T4-39 |
446 |
Nil |
NA |
198/181 |
LG-751 HG-317 |
- |
- |
40 (17-77) |
-Age -LVI -pT -pN -Location |
RFS CSS |
6 |
61. |
Xu 201861 Xu H, Tan P, Jin X, Ai J, Lin T, Lei H, et al. Validation of the preoperative controlling nutritional status score as an independent predictor in a large Chinese cohort of patients with upper tract urothelial carcinoma. Cancer Med. 2018;7:6112-23. Epub 2018/11/30. China |
662 |
R |
N |
67 (59-74) |
376/286 |
O-430 L-232 |
Y |
≤pT2-338 >pT3-324 |
100 |
Nil |
NA |
349/193 |
LG-169 HG-493 |
279 |
149 |
42 (19-72) |
-Grade -pT -L.Node -Variant Histology -CONUT score |
OS RFS CSS |
6 |
62. |
Shibing 201649 Shibing Y, Liangren L, Qiang W, Hong L, Turun S, Junhao L, et al. Impact of tumour size on prognosis of upper urinary tract urothelial carcinoma after radical nephroureterectomy: a multi-institutional analysis of 795 cases. BJU Int. 2016;118:902-10. Epub 2016/03/05. China |
795 |
R |
Y |
NA |
462/333 |
O-588 L-207 |
Y |
Tis/Ta/T1-149 T2-241 T3-313 T4-92 |
169 |
Nil |
NA |
497/187 |
LG-212 HG-583 |
202 |
162 |
32 (17-60) |
-Grade -pT -LVI -Variant Histology -Size -Lymph.Node |
OS CSS RFS |
7 |
63. |
Zamboni 201962 Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupret M, Colin P, et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int. 2019;124:738-45. Epub 2019/03/26. Multicentre |
1610 |
R |
Y |
69 (61-76) |
1096/512 |
O-999 L-489 |
Y |
T0/Ta/Tis-401 T1-330 T2—227 T3-521 T4-110 |
344 |
235 |
NA |
NA |
HG-1058 |
233 |
150 |
42 |
-micropapillary variant -T3-4 stage -Sarcomatoid variant |
RFS CSM |
6 |
|
|
35714 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|